Cidara is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives that have the potential to transform the standard of care and save or improve patientsâ lives. Cidara is currently advancing its novel echinocandin antifungal, rezafungin acetate, in a Phase 3 clinical trial for the first-line treatment of candidemia and/or invasive candidiasis (ReSTORE). A second Phase 3 trial of once-weekly rezafungin for prophylaxis against invasive fungal infections in patients undergoing allogeneic blood and marrow transplantation (ReSPECT) is planned pending adequate funding and approval from the relevant regulatory authorities. In addition to its robust rezafungin clinical program, Cidara is applying its proprietary CloudbreakÂŽ platform to develop antiviral conjugates (AVCs) for the prevention and treatment of influenza and other viral diseases. The Cloudbreak platform is designed to discover compounds that both directly kill pathogens and direct a patientâs immune system to attack and eliminate pathogens. Cidara is headquartered in San Diego, California. Source
No articles found.
Oracle Health is developing a Digital Health Insertable (Under The Skin) Cardiac D...
Oracle Health is developing a Digital Health In...
Aduro is dedicated to its mission to discover, develop, and commercialize immunoth...
Aduro is dedicated to its mission to discover, ...
As of June 30, 2019, Sabraâs investment portfolio included 432 real estate prope...
As of June 30, 2019, Sabraâs investment portf...
Our mission is to educate and provide an affordable early detection system for the...
Our mission is to educate and provide an afford...
Aoxing Pharmaceutical Company Inc., is a specialty pharmaceutical company. The Com...
Aoxing Pharmaceutical Company Inc., is a specia...
Join the National Investor Network and get the latest information with your interests in mind.